RU2018145311A - Способы лечения рака - Google Patents
Способы лечения рака Download PDFInfo
- Publication number
- RU2018145311A RU2018145311A RU2018145311A RU2018145311A RU2018145311A RU 2018145311 A RU2018145311 A RU 2018145311A RU 2018145311 A RU2018145311 A RU 2018145311A RU 2018145311 A RU2018145311 A RU 2018145311A RU 2018145311 A RU2018145311 A RU 2018145311A
- Authority
- RU
- Russia
- Prior art keywords
- amino acid
- acid position
- cancer
- wild
- type
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 35
- 206010028980 Neoplasm Diseases 0.000 title claims 18
- 201000011510 cancer Diseases 0.000 title claims 18
- 235000001014 amino acid Nutrition 0.000 claims 25
- 150000001413 amino acids Chemical group 0.000 claims 25
- 108090000623 proteins and genes Proteins 0.000 claims 16
- 230000035772 mutation Effects 0.000 claims 15
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 claims 14
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 claims 14
- 230000037433 frameshift Effects 0.000 claims 13
- 239000003112 inhibitor Substances 0.000 claims 13
- 230000014509 gene expression Effects 0.000 claims 9
- 108020004485 Nonsense Codon Proteins 0.000 claims 8
- 230000037434 nonsense mutation Effects 0.000 claims 8
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 5
- 208000024891 symptom Diseases 0.000 claims 5
- 201000008271 Atypical teratoid rhabdoid tumor Diseases 0.000 claims 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 4
- 101000835860 Homo sapiens SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1 Proteins 0.000 claims 4
- 208000000172 Medulloblastoma Diseases 0.000 claims 4
- 208000008938 Rhabdoid tumor Diseases 0.000 claims 4
- 102100025746 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1 Human genes 0.000 claims 4
- 230000022131 cell cycle Effects 0.000 claims 4
- 230000004031 neuronal differentiation Effects 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 230000005760 tumorsuppression Effects 0.000 claims 4
- 102100034580 AT-rich interactive domain-containing protein 1A Human genes 0.000 claims 3
- 101150020330 ATRX gene Proteins 0.000 claims 3
- 102100024352 Dedicator of cytokinesis protein 4 Human genes 0.000 claims 3
- 101000924266 Homo sapiens AT-rich interactive domain-containing protein 1A Proteins 0.000 claims 3
- 101001052955 Homo sapiens Dedicator of cytokinesis protein 4 Proteins 0.000 claims 3
- 101000970561 Homo sapiens Myc box-dependent-interacting protein 1 Proteins 0.000 claims 3
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 claims 3
- 101000591201 Homo sapiens Receptor-type tyrosine-protein phosphatase kappa Proteins 0.000 claims 3
- 102100021970 Myc box-dependent-interacting protein 1 Human genes 0.000 claims 3
- 102000012850 Patched-1 Receptor Human genes 0.000 claims 3
- 108010065129 Patched-1 Receptor Proteins 0.000 claims 3
- 102100040120 Prominin-1 Human genes 0.000 claims 3
- 102100034089 Receptor-type tyrosine-protein phosphatase kappa Human genes 0.000 claims 3
- 102100023931 Transcriptional regulator ATRX Human genes 0.000 claims 3
- 108700042462 X-linked Nuclear Proteins 0.000 claims 3
- 108010016200 Zinc Finger Protein GLI1 Proteins 0.000 claims 3
- 102100035535 Zinc finger protein GLI1 Human genes 0.000 claims 3
- 230000037430 deletion Effects 0.000 claims 3
- 238000012217 deletion Methods 0.000 claims 3
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 230000005764 inhibitory process Effects 0.000 claims 3
- 230000037361 pathway Effects 0.000 claims 3
- 239000004475 Arginine Substances 0.000 claims 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 2
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 claims 2
- 241000289669 Erinaceus europaeus Species 0.000 claims 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 2
- 108010036115 Histone Methyltransferases Proteins 0.000 claims 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- 102100033254 Tumor suppressor ARF Human genes 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- 235000009582 asparagine Nutrition 0.000 claims 2
- 229960001230 asparagine Drugs 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 2
- 235000013922 glutamic acid Nutrition 0.000 claims 2
- 239000004220 glutamic acid Substances 0.000 claims 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- -1 CKDN1A Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 230000009459 hedgehog signaling Effects 0.000 claims 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 108700024542 myc Genes Proteins 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 1
- 230000008410 smoothened signaling pathway Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
Applications Claiming Priority (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261714145P | 2012-10-15 | 2012-10-15 | |
| US201261714140P | 2012-10-15 | 2012-10-15 | |
| US201261714045P | 2012-10-15 | 2012-10-15 | |
| US61/714,140 | 2012-10-15 | ||
| US61/714,145 | 2012-10-15 | ||
| US61/714,045 | 2012-10-15 | ||
| US201361758972P | 2013-01-31 | 2013-01-31 | |
| US61/758,972 | 2013-01-31 | ||
| US201361780703P | 2013-03-13 | 2013-03-13 | |
| US61/780,703 | 2013-03-13 | ||
| US201361786277P | 2013-03-14 | 2013-03-14 | |
| US61/786,277 | 2013-03-14 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015118144A Division RU2677276C2 (ru) | 2012-10-15 | 2013-10-15 | Способы лечения рака |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2018145311A true RU2018145311A (ru) | 2019-02-18 |
Family
ID=49519104
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018145311A RU2018145311A (ru) | 2012-10-15 | 2013-10-15 | Способы лечения рака |
| RU2015118144A RU2677276C2 (ru) | 2012-10-15 | 2013-10-15 | Способы лечения рака |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015118144A RU2677276C2 (ru) | 2012-10-15 | 2013-10-15 | Способы лечения рака |
Country Status (23)
| Country | Link |
|---|---|
| US (7) | US9688665B2 (enExample) |
| EP (2) | EP3659606A1 (enExample) |
| JP (5) | JP6351182B2 (enExample) |
| KR (3) | KR102021642B1 (enExample) |
| CN (2) | CN105142642B (enExample) |
| AU (4) | AU2013331368A1 (enExample) |
| BR (1) | BR112015008447A2 (enExample) |
| CA (2) | CA3177498A1 (enExample) |
| CY (1) | CY1122186T1 (enExample) |
| ES (1) | ES2750199T3 (enExample) |
| HR (1) | HRP20191814T1 (enExample) |
| HU (1) | HUE046790T2 (enExample) |
| IL (4) | IL288181B2 (enExample) |
| LT (1) | LT2908823T (enExample) |
| MX (2) | MX376008B (enExample) |
| NZ (2) | NZ706836A (enExample) |
| PL (1) | PL2908823T3 (enExample) |
| PT (1) | PT2908823T (enExample) |
| RS (1) | RS59541B1 (enExample) |
| RU (2) | RU2018145311A (enExample) |
| SI (1) | SI2908823T1 (enExample) |
| SM (1) | SMT201900593T1 (enExample) |
| WO (1) | WO2014062720A2 (enExample) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2841142C (en) | 2010-06-23 | 2020-12-15 | Ryan D. Morin | Biomarkers for non-hodgkin lymphomas and uses thereof |
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| EP2780013A4 (en) | 2011-11-18 | 2015-07-01 | Constellation Pharmaceuticals Inc | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF |
| US9085583B2 (en) | 2012-02-10 | 2015-07-21 | Constellation—Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| PL3628670T3 (pl) | 2012-04-13 | 2023-02-20 | Epizyme, Inc. | Postać soli dla inhibicji ezh2 |
| MX376008B (es) | 2012-10-15 | 2025-03-07 | Epizyme Inc | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. |
| SG10201705989YA (en) | 2012-10-15 | 2017-08-30 | Epizyme Inc | Substituted benzene compounds |
| EP3498701B1 (en) | 2012-12-21 | 2023-02-22 | Epizyme Inc | Prmt5 inhibitors and uses thereof |
| EP2970305B1 (en) | 2013-03-15 | 2017-02-22 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2015023915A1 (en) | 2013-08-15 | 2015-02-19 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
| SI3057962T1 (sl) | 2013-10-16 | 2024-01-31 | Epizyme, Inc. | Oblika hidrokloridne soli za ezh2 inhibicijo |
| AU2014337121A1 (en) * | 2013-10-18 | 2016-04-14 | Epizyme, Inc. | Method of treating cancer |
| KR20220165809A (ko) | 2013-12-06 | 2022-12-15 | 에피자임, 인코포레이티드 | 암 치료를 위한 병용 요법 |
| PL3157527T3 (pl) * | 2014-06-17 | 2023-08-07 | Epizyme, Inc. | Inhibitory ezh2 do leczenia chłoniaka |
| MX384423B (es) | 2014-06-19 | 2025-03-14 | Memorial Sloan Kettering Cancer Center | Biomarcadores para la respuesta a inhibidores del mejorador del homólogo 2 de zeste (ezh2). |
| CA2963149A1 (en) * | 2014-10-16 | 2016-04-21 | Epizyme, Inc. | Method for treating cancer |
| HUE062159T2 (hu) * | 2014-11-17 | 2023-10-28 | Epizyme Inc | Módszer a rák kezelésére N-((4,6-dimetil-2-oxo-l,2-dihidropiridin-3-il)metil)-5-(etil(tetrahidro-2H -pirán-4-il)amino)-4-metil-4'-(morfolinmetil)-[1,1'-bifenil]-3-karboxamiddal |
| TW201636344A (zh) | 2014-12-05 | 2016-10-16 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| EP3236962A2 (en) | 2014-12-23 | 2017-11-01 | University of Copenhagen | Treatment of cancer by inhibiting ezh2 activity |
| MX391720B (es) * | 2015-04-20 | 2025-03-21 | Epizyme Inc | Terapia combinada para tratar cáncer. |
| JP6890097B2 (ja) * | 2015-06-10 | 2021-06-18 | エピザイム，インコーポレイティド | リンパ腫を処置するためのｅｚｈ２阻害剤 |
| MX2018002344A (es) | 2015-08-24 | 2018-07-06 | Epizyme Inc | Metodo para tratar el cancer. |
| TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| US10577350B2 (en) | 2015-08-28 | 2020-03-03 | Constellation Pharmaceuticals, Inc. | Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide |
| AU2016325643B2 (en) * | 2015-09-25 | 2022-07-21 | Epizyme, Inc. | Method of treating malignant rhabdoid tumor or small cell cancer of the ovary of the hypercalcemic type |
| KR20180058829A (ko) * | 2015-10-06 | 2018-06-01 | 에피자임, 인코포레이티드 | Ezh2 억제제로 수모세포종을 치료하는 방법 |
| JP2018532761A (ja) * | 2015-11-06 | 2018-11-08 | エピザイム，インコーポレイティド | Ｅｚｈ２阻害剤を用いた癌の処置のための小児投与 |
| CN105440023A (zh) * | 2015-12-10 | 2016-03-30 | 江苏理工学院 | Epz-6438的合成方法 |
| EP3407978A4 (en) | 2016-01-29 | 2020-01-15 | Epizyme Inc | POLYTHERAPY FOR THE TREATMENT OF CANCER |
| WO2017139404A1 (en) * | 2016-02-08 | 2017-08-17 | Epizyme, Inc. | Methods of treating cancer |
| WO2017201585A1 (en) * | 2016-05-26 | 2017-11-30 | Genea Ip Holdings Pty Ltd | Modulators of dux4 for regulation of muscle function |
| CA3025933A1 (en) | 2016-06-01 | 2017-12-07 | Epizyme, Inc. | Use of ezh2 inhibitors for treating cancer |
| WO2017214373A1 (en) * | 2016-06-08 | 2017-12-14 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| JP2019521988A (ja) | 2016-06-17 | 2019-08-08 | エピザイム，インコーポレイティド | 癌を処置するためのｅｚｈ２阻害剤 |
| WO2018034801A1 (en) * | 2016-08-15 | 2018-02-22 | The Wistar Institute Of Anatomy And Biology | Methods of treating arid1a-mutated cancers with hdac6 inhibitors and ezh2 inhibitors |
| US11433068B2 (en) * | 2016-09-08 | 2022-09-06 | The General Hospital Corporation | Treatment of cancers having alterations within the SWI/SNF chromatin remodeling complex |
| WO2018075598A1 (en) | 2016-10-19 | 2018-04-26 | Constellation Pharmaceuticals, Inc. | Synthesis of inhibitors of ezh2 |
| CA3044691A1 (en) | 2016-10-26 | 2018-05-03 | Genea Biocells USA (Holdings), Inc. | Improved generation of muscle lineage cells and therapeutic uses thereof |
| CN108314677B (zh) | 2017-01-17 | 2020-06-30 | 安徽中科拓苒药物科学研究有限公司 | 一种ezh2抑制剂及其用途 |
| EP3576729A4 (en) * | 2017-02-02 | 2021-04-14 | Epizyme, Inc. | CANCER TREATMENT MODALITIES |
| US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
| US11642346B2 (en) | 2017-03-31 | 2023-05-09 | Epizyme, Inc. | Combination therapy for treating cancer |
| JP2020522687A (ja) | 2017-06-02 | 2020-07-30 | エピザイム，インコーポレイティド | 癌を処置するためのｅｚｈ２阻害剤の使用 |
| WO2019018635A1 (en) | 2017-07-19 | 2019-01-24 | Children's Medical Center Corporation | COMPOSITIONS AND METHODS FOR TREATING DISEASES ASSOCIATED WITH IMPRESSIVE FAULT |
| KR102758037B1 (ko) | 2017-08-18 | 2025-01-22 | 코테라 바이오사이언스 인코포레이티드 | Tg02의 다형성 형태 |
| EP3678663A4 (en) | 2017-09-05 | 2021-06-02 | Epizyme, Inc. | POLYTHERAPY FOR CANCER TREATMENT |
| CA3082287C (en) | 2017-11-14 | 2023-02-28 | Pfizer Inc. | Ezh2 inhibitor combination therapies |
| PT4043466T (pt) | 2018-01-31 | 2024-10-14 | Mirati Therapeutics Inc | Inibidores de prc2 |
| WO2020011607A1 (en) * | 2018-07-09 | 2020-01-16 | Fondation Asile Des Aveugles | Inhibition of prc2 subunits to treat eye disorders |
| TWI798532B (zh) * | 2019-03-25 | 2023-04-11 | 大陸商深圳微芯生物科技股份有限公司 | Ｋｄｍ５ａ基因和ａｔｒｘ基因的應用 |
| US20220154295A1 (en) * | 2019-03-27 | 2022-05-19 | The Johns Hopkins University | Methods and materials for assessing and treating cancer |
| WO2020219606A1 (en) | 2019-04-22 | 2020-10-29 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Use of erk5 inhibitors for treating gliomas in pediatric subjects |
| EP3959214A1 (en) | 2019-04-22 | 2022-03-02 | Mirati Therapeutics, Inc. | Naphthyridine derivatives as prc2 inhibitors |
| WO2020247130A1 (en) * | 2019-06-03 | 2020-12-10 | Icahn School Of Medicine At Mount Sinai | Compounds and methods for inhibiting cancers via rest inhibition |
| EP3980422A1 (en) | 2019-06-05 | 2022-04-13 | Mirati Therapeutics, Inc. | Imidazo[1,2-c]pyrimidine derivatives as prc2 inhibitors for treating cancer |
| CN114126651A (zh) | 2019-06-28 | 2022-03-01 | Als治疗发展学会 | 对二肽重复蛋白的抑制 |
| US20230181543A1 (en) * | 2020-02-28 | 2023-06-15 | The Wistar Institute Of Anatomy And Biology | Treatment of carm1-overexpressing and/or arid1a mutant cancers with ire-1/xbp-1 inhibitors |
| WO2021257842A1 (en) * | 2020-06-18 | 2021-12-23 | Epizyme, Inc. | Smarca4 inhibition for the treatment of cancer |
| CN111773387A (zh) * | 2020-07-08 | 2020-10-16 | 北京大学 | 一种通过改变bin1剪切体比例改善心脏横管结构的方法 |
| US20240350508A1 (en) | 2021-08-25 | 2024-10-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of ezh2 inhibitors for the treatment of aortic valve stenosis |
| CN116019916A (zh) * | 2021-10-27 | 2023-04-28 | 蚌埠医学院第一附属医院 | 非小细胞肺癌靶点arid1a及其抑制剂在制备肺癌治疗药物中的用途 |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5455044A (en) | 1993-05-14 | 1995-10-03 | Depotech Corporation | Method for treating neurological disorders |
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| US7229774B2 (en) | 2001-08-02 | 2007-06-12 | Regents Of The University Of Michigan | Expression profile of prostate cancer |
| EP1638541B1 (en) | 2003-06-27 | 2010-05-19 | Astellas Pharma Inc. | Therapeutic agent for soft tissue sarcoma |
| WO2009006577A2 (en) * | 2007-07-03 | 2009-01-08 | The Regents Of The University Of Michigan | Compositions and methods for inhibiting ezh2 |
| US20120114670A1 (en) * | 2007-10-02 | 2012-05-10 | University Of Rochester | Methods and compositions related to synergistic responses to oncogenic mutations |
| WO2009048958A2 (en) * | 2007-10-08 | 2009-04-16 | The Board Of Regents Of The University Of Texas System | Methods and compositions involving chitosan nanoparticles |
| US20110251216A1 (en) | 2010-02-19 | 2011-10-13 | The Regents Of The University Of Michigan | Compositions and methods for inhibiting ezh2 |
| US8637509B2 (en) | 2010-05-07 | 2014-01-28 | Glaxosmithkline Llc | Azaindazoles |
| EP2566327B1 (en) | 2010-05-07 | 2017-03-29 | Glaxosmithkline LLC | Indoles |
| WO2011140325A1 (en) | 2010-05-07 | 2011-11-10 | Glaxosmithkline Llc | Indazoles |
| WO2012071096A2 (en) * | 2010-09-03 | 2012-05-31 | The Johns Hopkins University | Arid1a and ppp2r1a mutations in cancer |
| PL2614369T3 (pl) * | 2010-09-10 | 2016-08-31 | Epizyme Inc | Sposób określania przydatności inhibitorów ludzkiego ezh2 w leczeniu |
| US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| WO2012068589A2 (en) * | 2010-11-19 | 2012-05-24 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| ES2607064T3 (es) | 2010-12-01 | 2017-03-29 | Glaxosmithkline Llc | Indoles |
| JP2014511389A (ja) | 2011-02-28 | 2014-05-15 | エピザイム インコーポレイテッド | 置換６，５−縮合二環式ヘテロアリール化合物 |
| EP2694677A2 (en) | 2011-04-04 | 2014-02-12 | Netherland Cancer Institute | Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors |
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| EP2709629B1 (en) | 2011-05-16 | 2017-10-11 | Ulrike Nuber | Novel cancer therapies and methods |
| EP2755962B1 (en) * | 2011-09-13 | 2017-03-01 | Glaxosmithkline LLC | Azaindazoles |
| BR112014007603A2 (pt) | 2011-09-30 | 2017-06-13 | Glaxosmithkline Llc | métodos de tratamento do câncer |
| WO2013059944A1 (en) | 2011-10-28 | 2013-05-02 | British Columbia Cancer Agency Branch | Epigenetic regulators and uses thereof |
| US9085583B2 (en) | 2012-02-10 | 2015-07-21 | Constellation—Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| EP2825161B1 (en) * | 2012-03-12 | 2019-01-02 | Epizyme, Inc. | Inhibitors of human ezh2, and methods of use thereof |
| EP2828250B1 (en) * | 2012-03-19 | 2021-03-10 | Imperial College Innovations Limited | Quinazoline compounds and their use in therapy |
| CN104768555B (zh) | 2012-04-13 | 2018-10-30 | Epizyme股份有限公司 | 用于治疗癌症的联合治疗 |
| PL3628670T3 (pl) | 2012-04-13 | 2023-02-20 | Epizyme, Inc. | Postać soli dla inhibicji ezh2 |
| WO2013173441A2 (en) * | 2012-05-16 | 2013-11-21 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| SG10201705989YA (en) | 2012-10-15 | 2017-08-30 | Epizyme Inc | Substituted benzene compounds |
| MX376008B (es) | 2012-10-15 | 2025-03-07 | Epizyme Inc | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. |
| US20140120083A1 (en) | 2012-11-01 | 2014-05-01 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| WO2014092905A1 (en) | 2012-12-10 | 2014-06-19 | Children's Medical Center Corporation | Methods and assays for combination treatment of cancer |
| AU2013361060B2 (en) | 2012-12-21 | 2018-04-19 | Epizyme, Inc. | 1,4-pyridone compounds |
| CA2894222A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | 1,4-pyridone bicyclic heteroaryl compounds |
| MA38341B1 (fr) | 2013-02-11 | 2018-11-30 | Constellation Pharmaceuticals Inc | Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées |
| US9045477B2 (en) | 2013-03-15 | 2015-06-02 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| US20160031907A1 (en) | 2013-03-15 | 2016-02-04 | Epizyme, Inc. | Substituted Benzene Compounds |
| US9243001B2 (en) | 2013-03-15 | 2016-01-26 | Epizyme, Inc. | Substituted benzene compounds |
| US9776996B2 (en) | 2013-03-15 | 2017-10-03 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| WO2014176047A1 (en) | 2013-04-25 | 2014-10-30 | Novartis Ag | Markers for ezh2 inhibitors |
| HK1214815A1 (zh) | 2013-04-30 | 2016-08-05 | Glaxosmithkline Intellectual Property (No. 2) Limited | Zeste增强子同源物2的抑制剂 |
| CN105452246A (zh) | 2013-06-06 | 2016-03-30 | 葛兰素史密斯克莱知识产权（第2号）有限公司 | Zeste增强子同源物2的抑制剂 |
| CN105473580A (zh) | 2013-07-10 | 2016-04-06 | 葛兰素史密斯克莱知识产权（第2号）有限公司 | Zeste同源物增强子2抑制剂 |
| WO2015010049A1 (en) | 2013-07-19 | 2015-01-22 | Epizyme, Inc. | Substituted benzene compounds |
| EP3022195A2 (en) | 2013-07-19 | 2016-05-25 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| SI3057962T1 (sl) | 2013-10-16 | 2024-01-31 | Epizyme, Inc. | Oblika hidrokloridne soli za ezh2 inhibicijo |
| AU2014337121A1 (en) | 2013-10-18 | 2016-04-14 | Epizyme, Inc. | Method of treating cancer |
| KR20220165809A (ko) | 2013-12-06 | 2022-12-15 | 에피자임, 인코포레이티드 | 암 치료를 위한 병용 요법 |
| WO2015103431A1 (en) | 2013-12-31 | 2015-07-09 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for the diagnosis and treatment of ovarian cancers that are associated with reduced smarca4 gene expression or protein function |
| US20160361309A1 (en) | 2014-02-26 | 2016-12-15 | Glaxosmithkline Intellectual Property (No.2) Limited | Methods of treating cancer patients responding to ezh2 inhibitor gsk126 |
| WO2015132765A1 (en) | 2014-03-07 | 2015-09-11 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
| EA201691872A1 (ru) | 2014-03-19 | 2017-04-28 | Инфинити Фармасьютикалз, Инк. | Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств |
| WO2015193768A1 (en) | 2014-06-17 | 2015-12-23 | Pfizer Inc. | Aryl fused lactams as ezh2 modulators |
| PL3157527T3 (pl) | 2014-06-17 | 2023-08-07 | Epizyme, Inc. | Inhibitory ezh2 do leczenia chłoniaka |
| MX384423B (es) | 2014-06-19 | 2025-03-14 | Memorial Sloan Kettering Cancer Center | Biomarcadores para la respuesta a inhibidores del mejorador del homólogo 2 de zeste (ezh2). |
| EP3160940A4 (en) | 2014-06-25 | 2018-05-02 | Epizyme, Inc. | Substituted benzene and 6,5-fused bicyclic heteroaryl compounds |
| BR112017004459A2 (pt) | 2014-09-05 | 2017-12-05 | Arqule Inc | composições e métodos para o tratamento de distúrbios de proliferação |
| CA2963149A1 (en) * | 2014-10-16 | 2016-04-21 | Epizyme, Inc. | Method for treating cancer |
| HUE062159T2 (hu) | 2014-11-17 | 2023-10-28 | Epizyme Inc | Módszer a rák kezelésére N-((4,6-dimetil-2-oxo-l,2-dihidropiridin-3-il)metil)-5-(etil(tetrahidro-2H -pirán-4-il)amino)-4-metil-4'-(morfolinmetil)-[1,1'-bifenil]-3-karboxamiddal |
| MX391720B (es) | 2015-04-20 | 2025-03-21 | Epizyme Inc | Terapia combinada para tratar cáncer. |
| JP6890097B2 (ja) | 2015-06-10 | 2021-06-18 | エピザイム，インコーポレイティド | リンパ腫を処置するためのｅｚｈ２阻害剤 |
| MX2018002344A (es) | 2015-08-24 | 2018-07-06 | Epizyme Inc | Metodo para tratar el cancer. |
| AU2016325643B2 (en) | 2015-09-25 | 2022-07-21 | Epizyme, Inc. | Method of treating malignant rhabdoid tumor or small cell cancer of the ovary of the hypercalcemic type |
| KR20180058829A (ko) | 2015-10-06 | 2018-06-01 | 에피자임, 인코포레이티드 | Ezh2 억제제로 수모세포종을 치료하는 방법 |
| JP2018532761A (ja) | 2015-11-06 | 2018-11-08 | エピザイム，インコーポレイティド | Ｅｚｈ２阻害剤を用いた癌の処置のための小児投与 |
| CN108697716A (zh) | 2015-12-07 | 2018-10-23 | Epizyme股份有限公司 | Ezh2抑制剂及其使用方法 |
| EP3407978A4 (en) | 2016-01-29 | 2020-01-15 | Epizyme Inc | POLYTHERAPY FOR THE TREATMENT OF CANCER |
| WO2017139404A1 (en) | 2016-02-08 | 2017-08-17 | Epizyme, Inc. | Methods of treating cancer |
| CA3025933A1 (en) | 2016-06-01 | 2017-12-07 | Epizyme, Inc. | Use of ezh2 inhibitors for treating cancer |
| WO2017214373A1 (en) | 2016-06-08 | 2017-12-14 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| JP2019521988A (ja) | 2016-06-17 | 2019-08-08 | エピザイム，インコーポレイティド | 癌を処置するためのｅｚｈ２阻害剤 |
| EP3576729A4 (en) | 2017-02-02 | 2021-04-14 | Epizyme, Inc. | CANCER TREATMENT MODALITIES |
| US11642346B2 (en) | 2017-03-31 | 2023-05-09 | Epizyme, Inc. | Combination therapy for treating cancer |
| JP2020522687A (ja) | 2017-06-02 | 2020-07-30 | エピザイム，インコーポレイティド | 癌を処置するためのｅｚｈ２阻害剤の使用 |
| WO2018231973A1 (en) | 2017-06-13 | 2018-12-20 | Epizyme, Inc. | Inhibitors of ezh2 and methods of use thereof |
| EP3678663A4 (en) | 2017-09-05 | 2021-06-02 | Epizyme, Inc. | POLYTHERAPY FOR CANCER TREATMENT |
| CA3162315A1 (en) | 2019-12-20 | 2021-06-24 | Marinus Jacobus Verwijs | Crystalline hydrobromide salt of a ezh2 inhibitor, its preparation and pharmaceutical composition useful for the treatment of cancer |
| CN115666725A (zh) | 2020-05-28 | 2023-01-31 | Epizyme股份有限公司 | Ezh2抑制剂用于治疗癌症的用途 |
-
2013
- 2013-10-15 MX MX2015004771A patent/MX376008B/es active IP Right Grant
- 2013-10-15 US US14/054,646 patent/US9688665B2/en active Active
- 2013-10-15 PL PL13786351T patent/PL2908823T3/pl unknown
- 2013-10-15 KR KR1020157012664A patent/KR102021642B1/ko active Active
- 2013-10-15 KR KR1020237037919A patent/KR20230156450A/ko not_active Ceased
- 2013-10-15 JP JP2015537017A patent/JP6351182B2/ja active Active
- 2013-10-15 NZ NZ706836A patent/NZ706836A/en unknown
- 2013-10-15 CA CA3177498A patent/CA3177498A1/en active Pending
- 2013-10-15 NZ NZ746054A patent/NZ746054A/en unknown
- 2013-10-15 CN CN201380065694.0A patent/CN105142642B/zh active Active
- 2013-10-15 ES ES13786351T patent/ES2750199T3/es active Active
- 2013-10-15 WO PCT/US2013/065112 patent/WO2014062720A2/en not_active Ceased
- 2013-10-15 RU RU2018145311A patent/RU2018145311A/ru unknown
- 2013-10-15 SM SM20190593T patent/SMT201900593T1/it unknown
- 2013-10-15 IL IL288181A patent/IL288181B2/en unknown
- 2013-10-15 CN CN201910862425.6A patent/CN110898067A/zh active Pending
- 2013-10-15 IL IL308613A patent/IL308613A/en unknown
- 2013-10-15 PT PT137863510T patent/PT2908823T/pt unknown
- 2013-10-15 RU RU2015118144A patent/RU2677276C2/ru active
- 2013-10-15 EP EP19199387.2A patent/EP3659606A1/en active Pending
- 2013-10-15 CA CA2887243A patent/CA2887243C/en active Active
- 2013-10-15 BR BR112015008447A patent/BR112015008447A2/pt not_active Application Discontinuation
- 2013-10-15 EP EP13786351.0A patent/EP2908823B1/en active Active
- 2013-10-15 HR HRP20191814TT patent/HRP20191814T1/hr unknown
- 2013-10-15 HU HUE13786351A patent/HUE046790T2/hu unknown
- 2013-10-15 KR KR1020197025972A patent/KR20190105669A/ko not_active Ceased
- 2013-10-15 AU AU2013331368A patent/AU2013331368A1/en not_active Abandoned
- 2013-10-15 LT LT13786351T patent/LT2908823T/lt unknown
- 2013-10-15 SI SI201331587T patent/SI2908823T1/sl unknown
- 2013-10-15 RS RS20191374A patent/RS59541B1/sr unknown
-
2015
- 2015-04-13 IL IL238254A patent/IL238254B/en active IP Right Grant
- 2015-04-15 MX MX2020010535A patent/MX2020010535A/es unknown
-
2017
- 2017-05-17 US US15/598,262 patent/US20170305890A1/en not_active Abandoned
- 2017-05-17 US US15/598,261 patent/US20170305889A1/en not_active Abandoned
-
2018
- 2018-01-29 JP JP2018012593A patent/JP2018062535A/ja not_active Withdrawn
- 2018-05-15 US US15/979,916 patent/US20190100514A1/en not_active Abandoned
- 2018-09-21 AU AU2018233004A patent/AU2018233004B2/en active Active
-
2019
- 2019-09-06 JP JP2019162839A patent/JP2020011971A/ja not_active Withdrawn
- 2019-10-18 CY CY20191101090T patent/CY1122186T1/el unknown
-
2020
- 2020-01-22 US US16/749,073 patent/US20200262823A1/en not_active Abandoned
- 2020-03-23 IL IL273517A patent/IL273517A/en unknown
- 2020-07-15 AU AU2020205261A patent/AU2020205261B2/en active Active
-
2021
- 2021-05-28 JP JP2021089951A patent/JP2021120420A/ja not_active Withdrawn
-
2022
- 2022-03-08 US US17/689,704 patent/US12162865B2/en active Active
-
2023
- 2023-12-13 AU AU2023282217A patent/AU2023282217A1/en active Pending
- 2023-12-21 JP JP2023215651A patent/JP2024029066A/ja active Pending
-
2024
- 2024-09-27 US US18/900,177 patent/US20250163033A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018145311A (ru) | Способы лечения рака | |
| MX2023011282A (es) | Analogos de rapamicina ligados a c40, c28 y c-32 como inhibidores de mtor. | |
| JP2018083821A5 (enExample) | ||
| IL258544A (en) | Combined treatment for cancer | |
| ZA201904234B (en) | Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof | |
| PH12020550256A1 (en) | 1-benzyl-2-imino-4-phenyl-5-oxoimidazolidine derivatives as hiv protease inhibitors | |
| JP2016020389A5 (enExample) | ||
| RU2014141045A (ru) | Ингибиторы ezh2 человека и способы их применения | |
| WO2013049770A3 (en) | Methods of treating cancer | |
| WO2018064589A9 (en) | Targeted protein degradation using a mutant e3 ubiquitin ligase | |
| UA108369C2 (uk) | Піролопіримідини як інгібітори cdk4/6 | |
| WO2016106404A3 (en) | Methods and compositions for treating malignant tumors associated with kras mutation | |
| EA201491018A1 (ru) | Новые бициклические производные дигидроизохинолин-1-она | |
| MX2019001132A (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1. | |
| EA200900064A1 (ru) | Ингибирование агрегации альфа-синуклеина | |
| CY1122364T1 (el) | Αναστολεις της ezh2 | |
| MX2014001372A (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico. | |
| EA201991884A2 (ru) | Ингибиторы g12c kras | |
| EA201790838A1 (ru) | Ингибитор киназы aurora a | |
| EA201290324A1 (ru) | Киназные ингибиторы | |
| PH12020551390A1 (en) | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | |
| MX2022001863A (es) | Metodos para tratar los tumores del estroma gastrointestinal. | |
| GB2550804A (en) | Method of treating disorders requiring destruction or removal of cells using a neural thread protein derived peptide | |
| WO2012094401A3 (en) | Genes frequently altered in pancreatic neuroendocrine tumors | |
| EA202090959A1 (ru) | Аминзамещенные гетероциклические соединения в качестве ингибиторов ehmt2, их соли и способы их синтеза |